FIELD: biotechnology.
SUBSTANCE: invention relates to low-viscosity protein compositions. Method of reducing the viscosity of a formulation comprising an antibody comprises a step of combining the antibody, a pharmaceutically acceptable solvent and thiamine or a pharmaceutically acceptable salt thereof, where the formulation contains at least 100 mg/ml of the antibody, from 0.10 M to 0.25 M of thiamine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvent, where the absolute viscosity of the formulation is less than the absolute viscosity of the control formulation containing the antibody and a pharmaceutically acceptable solvent, but without thiamine or a pharmaceutically acceptable salt thereof.
EFFECT: invention provides concentrated low-volume liquid pharmaceutical formulations of proteins with low viscosity.
14 cl, 9 dwg, 40 tbl, 28 ex
Title | Year | Author | Number |
---|---|---|---|
LIQUID COMPOSITIONS OF PROTEINS CONTAINING AGENTS FOR VISCOSITY REDUCTION | 2014 |
|
RU2710542C2 |
LIQUID PROTEIN COMPOSITIONS CONTAINING VISCOSITY-REDUCING AGENTS | 2014 |
|
RU2782765C2 |
LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | 2014 |
|
RU2675824C2 |
CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
PHARMACEUTICAL FORMULATION CONTAINING BEVACIZUMAB | 2021 |
|
RU2819797C1 |
ANTIBODY FORMULATIONS | 2012 |
|
RU2665810C2 |
BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR LONG-TERM RELEASE OF PROTEIN | 2013 |
|
RU2676102C2 |
HIGH-CONCENTRATION LIQUID ANTI-EGFR ANTIBODY COMPOSITIONS | 2005 |
|
RU2390353C2 |
SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
V1A-RECEPTORS AGONISTS | 2013 |
|
RU2634617C2 |
Authors
Dates
2025-02-03—Published
2022-10-28—Filed